Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q1fy27: Net Revenue Dips, CDMO Segment Struggles
Dishman Carbogen Amcis Limited (DCAL) reports Q1FY27 results with net revenue dipping 4.29%, driven by CDMO segment decline.
Dishman Carbogen Amcis Limited (DCAL) has reported its financial results for the first quarter of FY27, revealing a net revenue of ₹6,776 million, a slight decline of 4.29% compared to ₹7,080 million in Q1FY26. The decrease is primarily attributed to a deferment of CDMO revenue, partially offset by growth in the Marketable Molecules (MM) segment.
Quarter Highlights
The CDMO revenue experienced a 12.6% year-over-year decline, mainly due to customer-requested rescheduling of project deliverables worth approximately CHF 10 million to the second half of the financial year. In contrast, the MM segment revenue surged by 48% in Q1 FY27 compared to Q1 FY26, driven by higher Cholesterol revenue.
Segment Performance
The EBITDA margin for the quarter stood at 8.9%, significantly down from 19.9% in Q1 FY26. The CDMO segment margin dropped to 6.3% from 17.9% in the same quarter last year due to deferred revenues and a notional foreign exchange loss of INR 117.3 million. Meanwhile, the MM segment margin declined to 18.6% from 32.4%, primarily due to higher sales of Cholesterol compared to Vitamin D Analogues.
Forward Outlook
Despite the current challenges, Dishman Carbogen Amcis Limited remains focused on improving capacity utilization by targeting small and mid-sized global biotech companies and diversifying across new geographies. The company continues to leverage its robust R&D capabilities and global presence to drive future growth.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock holds at 32% of its 52-week range with RSI at 51. In other words, neither side has a clear edge right now. Revenue grows at 8.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dishman Carbogen Amcis Limited.
Biotechnology
Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.
Key Financial Highlights
The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.
Segment Performance
The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.
However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.
As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.
BIOCON
Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection
Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.
Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.
Expanding Access to Affordable Biologics
Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
Strengthening Oncology Portfolio
Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.
As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
BIOCON
Biocon Limited Q2 FY27: Revenue Up 2%, Ebitda Margin Declines
Biocon Limited’s Q2 FY27 results show a 2% revenue increase, with EBITDA margin decline; strong biosimilars and generics performance.
Biocon Limited (BIOCON) reported its Q2 FY27 results, showing a 2% increase in revenue to ₹4,423 Cr compared to ₹4,389 Cr in the same period last year. The company’s EBITDA margin, however, declined to 20% from 22% in Q2 FY26. The focus remains on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital.
Biosimilars Performance
The Biosimilars segment recorded revenue of ₹2,809 Cr, up 3% YoY. EBITDA stood at ₹623 Cr with a 22% margin. The segment’s performance was impacted by the timing of revenue recognition on certain shipments. The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility.
Generics Segment
The Generics segment saw a 10% YoY revenue growth to ₹774 Cr. EBITDA margin expanded by over 700bps YoY to 8%. Liraglutide is gaining traction across markets, strengthening the complex injectables portfolio.
Services Division
The Services division revenue stood at ₹833 Cr, up 13% QoQ. EBITDA margin improved by 500bps QoQ to 20%. The division expects further improvement in the second half of the fiscal year.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2 FY27: Disbursements Rise 62% Qoq and PAT Grows 28%
-
Capital Markets3 days agoMaster Trust Limited (mastertr): Mastercapitalservices Raises ₹75 Cr Through Ncds
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Investor Presentation Q2 & H1 FY27 Highlights
-
Healthcare3 days agoZydus Lifesciences Limited (zyduslife) Inspection by USFDA Concludes at Liqmeds, UK
-
Financial Services3 days agoSammaan Capital Limited (sammaancap) Q2fy27 Investor Presentation: Strong Growth and Expansion
-
MAXESTATES2 days agoMax Estates Limited (maxestates) Reimagines Luxury Living Through ‘the Bungalows’
-
Consumer Cyclical3 days agoSenco Gold Limited (senco) Q2 FY27: Revenue Growth of 34%, Retail Expansion Adds 14 Showrooms
-
Communication Equipment3 days agoTamilnadu Telecommunication Limited (tntele) Reports Q2 FY27: Net Loss Deepens
